5-(cyclohexylmethyl)-4-(3,5-ditert-butylphenyl)-N-(2-hydroxy-2-methylpropyl)pyrimidine-2-carboxamide
C30H45N3O2 — CID 118186098
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-(cyclohexylmethyl)-4-(3,5-ditert-butylphenyl)-N-(2-hydroxy-2-methylpropyl)pyrimidine-2-carboxamide
5-(cyclohexylmethyl)-4-(3,5-ditert-butylphenyl)-N-(2-hydroxy-2-methylpropyl)pyrimidine-2-carboxamide (PubChem CID 118186098) has the molecular formula C30H45N3O2 and a molecular weight of 479.71 g/mol. Its IUPAC name is 5-(cyclohexylmethyl)-4-(3,5-ditert-butylphenyl)-N-(2-hydroxy-2-methylpropyl)pyrimidine-2-carboxamide.
Molecular Properties
| Compound Name | 5-(cyclohexylmethyl)-4-(3,5-ditert-butylphenyl)-N-(2-hydroxy-2-methylpropyl)pyrimidine-2-carboxamide |
|---|---|
| PubChem CID | 118186098 |
| Molecular Formula | C30H45N3O2 |
| Molecular Weight | 479.71 g/mol |
| Exact Mass | 479.35 |
| IUPAC Name | 5-(cyclohexylmethyl)-4-(3,5-ditert-butylphenyl)-N-(2-hydroxy-2-methylpropyl)pyrimidine-2-carboxamide |
| SMILES | CC(C)(O)CNC(=O)c1ncc(CC2CCCCC2)c(-c2cc(C(C)(C)C)cc(C(C)(C)C)c2)n1 |
| InChI | InChI=1S/C30H45N3O2/c1-28(2,3)23-15-21(16-24(17-23)29(4,5)6)25-22(14-20-12-10-9-11-13-20)18-31-26(33-25)27(34)32-19-30(7,8)35/h15-18,20,35H,9-14,19H2,1-8H3,(H,32,34) |
| InChIKey | QUGMPTGCIARJIX-UHFFFAOYSA-N |
| XLogP | 6.36 |
| TPSA | 75.11 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 35 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 479.71 |
| LogP ≤ 5 | 6.36 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 118186098 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.